TY - JOUR
T1 - A partnership between community pharmacists and general practitioners in the management of ischaemic heart disease: A feasibility study
AU - Ryan-Woolley, Bernadette
AU - Cantrill, Judith
AU - Noyce, Peter
AU - Bennett, Elizabeth
AU - Geoghegan, Margaret
AU - Murphy, Martin
PY - 2001/9/15
Y1 - 2001/9/15
N2 - AIM • To explore the feasibility of pharmacist involvement in the management of patients with stable angina, when working with general practitioners (GPs). DESIGN • Protocol guided management of patients with stable angina. The study involved two face-to-face reviews conducted in general practices at the beginning and end of the five-month study and two brief interim telephone reviews. The patient reviews concentrated on six evidence-based interventions: smoking cessation, dietary advice, exercise, aspirin, beta-blockers and statins. SUBJECTS AND SETTING • The feasibility study was undertaken by five community pharmacists working in eight general practices within St Helens and Knowsley Health Authority, an area with a high ischaemic heart disease standardised mortality rate. 327 patients with stable angina (grades I-III, Canadian Cardiovascular Society classification criteria) were invited to participate in the study. OUTCOME MEASURES • Changes in: patient management across the six evidence-based interventions; angina grade assessed using the Canadian Cardiovascular Society classification criteria; quality of life and functional status assessed using the Seattle Angina Questionnaire. RESULTS • 236 (72%) of the invited patients participated in the study. 208 (88%) remained in the study until completion. Their mean age was 65 years (44-77 years); 94 (40%) were female and 142 (60%) were male. 105 therapeutic interventions were suggested by the pharmacists following the first patient reviews. 93 (89%) were accepted and included those relating to the sub-optimal use of nitrates. Improvements were seen as a consequence of both therapeutic and lifestyle interventions, the outcome of which was improved disease specific quality of life. CONCLUSIONS • The community pharmacists demonstrated their ability to work with general practitioners to deliver a specified model of care for the secondary prevention of ischaemic heart disease.
AB - AIM • To explore the feasibility of pharmacist involvement in the management of patients with stable angina, when working with general practitioners (GPs). DESIGN • Protocol guided management of patients with stable angina. The study involved two face-to-face reviews conducted in general practices at the beginning and end of the five-month study and two brief interim telephone reviews. The patient reviews concentrated on six evidence-based interventions: smoking cessation, dietary advice, exercise, aspirin, beta-blockers and statins. SUBJECTS AND SETTING • The feasibility study was undertaken by five community pharmacists working in eight general practices within St Helens and Knowsley Health Authority, an area with a high ischaemic heart disease standardised mortality rate. 327 patients with stable angina (grades I-III, Canadian Cardiovascular Society classification criteria) were invited to participate in the study. OUTCOME MEASURES • Changes in: patient management across the six evidence-based interventions; angina grade assessed using the Canadian Cardiovascular Society classification criteria; quality of life and functional status assessed using the Seattle Angina Questionnaire. RESULTS • 236 (72%) of the invited patients participated in the study. 208 (88%) remained in the study until completion. Their mean age was 65 years (44-77 years); 94 (40%) were female and 142 (60%) were male. 105 therapeutic interventions were suggested by the pharmacists following the first patient reviews. 93 (89%) were accepted and included those relating to the sub-optimal use of nitrates. Improvements were seen as a consequence of both therapeutic and lifestyle interventions, the outcome of which was improved disease specific quality of life. CONCLUSIONS • The community pharmacists demonstrated their ability to work with general practitioners to deliver a specified model of care for the secondary prevention of ischaemic heart disease.
M3 - Article
SN - 2053-6186
VL - 267
SP - 355
EP - 358
JO - Pharmaceutical Journal
JF - Pharmaceutical Journal
IS - 7165
ER -
